# RLYB catalysts: Rallybio Corp PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/rlyb/catalysts

> Rallybio Corp (RLYB) has 1 upcoming catalyst. The next is the AVZO-023 interim data readout, late 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for RLYB?

Rallybio Corp (RLYB) has 1 upcoming catalyst. The next is the AVZO-023 interim data readout, late 2028. Press release filed with the SEC (EX-99): "With the additional $215 million expected to be raised as part of this transaction, in addition to the current cash on our balance sheet, we expect to have sufficient runway into late 2028 to advance our clinical-stage programs through multiple clinical milestones, including updated Phase 1 data across the pipeline, initial clinical data for the combination of AVZO-023 and AVZO-021 with fulvestrant, and the initiation of multiple Phase 2 studies." [Calendar and source filings](https://sec-api.dev/companies/rlyb/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001193125-26-249790, https://www.sec.gov/Archives/edgar/data/1739410/000119312526249790/d19106dex993.htm (retrieved 2026-11-12). Last confirmed 2026-06-01. Cite: https://sec-api.dev/companies/rlyb/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Rallybio Corp |
| Ticker | RLYB (Nasdaq) |
| SEC CIK | 1739410 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/rlyb |

## Cash runway

Cash $90.7M as of 2026-09-30; quarterly burn $2.3M; about 119.5 months of runway at that rate (XBRL company facts, accession 0001628280-26-067422).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2024 | [RLYB212 trial start](https://sec-api.dev/pdufa/rlyb212) | RLYB |  | completed | "The Company received regulatory approval to begin the Phase 2 trial in October 2024 and initiated screening in November 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739410/000173941025000029/rlyb-20250313xex991pressre.htm)) |
| March 13, 2025 | [Rallybio Corp earnings report](https://sec-api.dev/companies/rlyb/catalysts) | RLYB |  | completed | "Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739410/000173941025000029/rlyb-20250313xex991pressre.htm)) |
| mid-2025 | [RLYB212 interim data readout](https://sec-api.dev/pdufa/rlyb212) | RLYB |  | scheduled | "•Rallybio expects to present interim data from the FNAIT natural history study in mid-2025, including data evaluating the frequency of FNAIT risk across racial and ethnic populations." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739410/000173941025000029/rlyb-20250313xex991pressre.htm)) |
| May 8, 2025 | [Rallybio Corp earnings report](https://sec-api.dev/companies/rlyb/catalysts) | RLYB |  | completed | "Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739410/000173941025000059/rlyb-2025058xex991pressrel.htm)) |
| August 7, 2025 | [Rallybio Corp earnings report](https://sec-api.dev/companies/rlyb/catalysts) | RLYB |  | completed | "Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739410/000173941025000108/rlyb-2025087xex991pressrel.htm)) |
| Q4 2025 | [RLYB116 topline data readout](https://sec-api.dev/pdufa/rlyb116) | RLYB |  | scheduled | ""With the RLYB116 confirmatory PK/PD study underway, we continue to look forward to the release of topline data from Cohort 1 and Cohort 2, expected in the third and fourth quarter of 2025, respectively."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739410/000173941025000108/rlyb-2025087xex991pressrel.htm)) |
| October 1, 2025 | [Anti-(integrin beta-3) human monoclonal antibody primary completion](https://sec-api.dev/pdufa/anti-integrin-beta-3-human-monoclonal-antibody) | RLYB | Fetal and Neonatal Alloimmune Thrombocytopenia | withdrawn | "NCT06435845 (Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Rallybio; Results First Posted 2026-03-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06435845)) |
| November 6, 2025 | [Rallybio Corp earnings report](https://sec-api.dev/companies/rlyb/catalysts) | RLYB |  | completed | "Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739410/000173941025000131/rlyb-2025116xex991pressrel.htm)) |
| late 2028 | [AVZO-023 interim data readout](https://sec-api.dev/pdufa/avzo-023) | RLYB |  | scheduled | "With the additional $215 million expected to be raised as part of this transaction, in addition to the current cash on our balance sheet, we expect to have sufficient runway into late 2028 to advance our clinical-stage programs through multiple clinical milestones, including updated Phase 1 data across the pipeline, initial clinical data for the combination of AVZO-023 and AVZO-021 with fulvestrant, and the initiation of multiple Phase 2 studies." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1739410/000119312526249790/d19106dex993.htm)) |

## Drugs

- [Anti-(integrin beta-3) human monoclonal antibody](https://sec-api.dev/pdufa/anti-integrin-beta-3-human-monoclonal-antibody): Fetal and Neonatal Alloimmune Thrombocytopenia
- [AVZO-023](https://sec-api.dev/pdufa/avzo-023): 
- [RLYB116](https://sec-api.dev/pdufa/rlyb116): 
- [RLYB212](https://sec-api.dev/pdufa/rlyb212): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/rlyb/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "RLYB catalysts: Rallybio Corp PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/rlyb/catalysts

```bibtex
@misc{secapidev_companies_rlyb_catalysts_20261116,
  title        = {RLYB catalysts: Rallybio Corp PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/rlyb/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_rlyb_catalysts_20261116","title":"RLYB catalysts: Rallybio Corp PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/rlyb/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
